Save the Date: Boston Will Become a Meeting Place for the Future of GI Oncology
10 Must-Read Posts in GU Oncology This Week
Marina Chiara Garassino Highlights Five-Year Follow-Up Results From the KEYNOTE-671 Trial in Resectable NSCLC
Amer Zeidan: Can All-Oral Therapy Reduce the Healthcare Burden for AML Patients?
10 Cancer Research Funding Opportunities to Know This November
Kevin Donaghy: When Stage IV Melanoma Changed the Meaning of Hope
Lived Experience Advocacy Hub Webinar Opportunity: AI in Oncology
Adagene Completes Phase 2 Enrollment for Muzastotug Plus Pembrolizumab in MSS Colorectal Cancer
Enter the Recurrence Score and clinical context to view the RS category and trial-aligned interpretation for early HR+/HER2- breast cancer.
This calculator is intended for ER/PR+ HER2- breast cancer only
TAILORx (Node-negative): Demonstrated that chemotherapy provides minimal to no benefit for most patients with RS 11-25. For patients ≤50 years, some benefit may be seen in RS 16-25.
RxPONDER (Node-positive, 1-3 nodes): Showed that postmenopausal patients with RS 0-25 did not benefit from chemotherapy. Premenopausal patients derived benefit regardless of RS.
RS Categories:
Low
0-10
Intermediate
11-25
High
26-100
Our calculators apply published formulas as precisely as we can. Even so, no formula captures every detail of a real patient. Use the result as one input to your own assessment, not the final word.
